anxiety depression distress Psychological symptoms anxiety depression distress Psychological symptoms
Conditions
Interventions
All participants are randomized into a control or intervention group.
The control group receive CAU. The intervention group will receive CAU and also
DWM. Namely, participants will receive access to
Sponsors
Vrije Universiteit
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Participants for the DWM trial must meet the following inclusion criteria: - 18 years or older. - Having elevated levels of psychological distress (Kessler Psychological Distress Scale; K10 >15.9). - Sufficient literacy and mastery (written and spoken) of one of the languages the DWM intervention is being delivered in (i.e., Dutch or English). - Having access to an electronic device with internet access to follow the intervention. - Written informed consent before entering the study.
Exclusion criteria
Exclusion criteria: Employees participating in DWM trial, will be excluded based on the following exclusion criteria: - Imminent suicide risk, or expressed acute needs or protection risks that require immediate follow-up. - Currently receiving specialized psychological treatment (e.g., EMDR or CBT) at the time of screening. - In case of current psychotropic medication use: being on an unstable dose for at least 2 months or a change in dosage over the past 2 months. - Having participated in the ASCEND trial (study phase 4a; cRCT #1; see research protocol) as supervisors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Study Phase 4b: The primary outcome will be the decrease in symptoms of anxiety and depression from baseline to 1-week post-intervention, measured through the sum score of the Patient Health Questionnaire (PHQ-9) and General Anxiety Disorder-7 (GAD-7), i.e. the PHQ-Anxiety and Depression Score (PHQ-ADS). We anticipate a greater reduction in symptoms of depression and anxiety for the DWM group compared to the control group at post-intervention. We expect to observe a Cohen's d effect size of 0.34 in favour of the DWM group one week after the intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| Study phase 4b: Secondary outcomes include level of anxiety (GAD-7) and depression (PHQ-9), resilience (Mainz Inventory of MIcrostressors, MIMIS), burnout (BAT-4), work engagement (UWES-3), absenteeism and presenteeism, self-stigma (SSOH-3), quality of life (EQ-5D-5L), and costs of care (CSRI). Additional study parameters will include demographic data, treatment fidelity, satisfaction with the intervention program, and implementation indicators (such as reach, adoption, appropriateness, acceptability, feasibility, use of DWM strategies, and resource use). Study phase 5: Focus group discussions and interviews conducted after the trial will assess the feasibility of scaling up the DWM intervention in Dutch small and medium organisations. | — |
Countries
Netherlands
Contacts
Public ContactC Gherdan
Vrije Universiteit
Outcome results
None listed